VivoSeq
Other

Bupivacaine

2

Pipeline Programs

11

Active Trials

3

Companies Involved

Bupivacaine is an early-stage landscape with 2 programs across 3 companies. The most active players are Heron Therapeutics, Grace Therapeutics Inc., AstraZeneca. 2 therapies are approved.

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

22/100

Mech. Concentration

100/100

Completion Rate

82/100

Attrition Rate

11/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs

Trial Status

118

clinical trials

Completed75 · 64%
Unknown status16 · 14%
Withdrawn7 · 6%
Recruiting6 · 5%
Terminated6 · 5%
Not yet recruiting4 · 3%
Other4 · 3%

Trial Activity

118 trials

Intrathecal Bupivacaine With or Without Dexmetomidine for Cesserian Delivery
Recruiting··Phase 2·NCT07465185·300 enrolled
Efficacy of EXPAREL vs. Bupivacaine
Recruiting·EEmory University·Phase 3·NCT07212114·104 enrolled
Bupivacaine and Epinephrine Injection Study
Recruiting··Phase 2/3·NCT06456255·80 enrolled
Bupivacaine With Epinephrine Over Diaphragm in Laparoscopy
Not yet recruiting··Phase 4·NCT07400146·100 enrolled
Mepivacaine Versus Bupivacaine Onset Time in Ultrasound-guided Ankle Blocks
Enrolling by invitation·MMayo Clinic·Phase 4·NCT05425979·50 enrolled
Page 1 of 8

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)